First-Line Chemotherapy for Advanced Breast Cancer

Greenspan E.M. . Results of four drug sequential combination chemotherapy of breast cancer in relation to predominant organ metastases. Proc Annu Meet Am Assoc Cancer Res. 1965; 6: 24. Abstract.

A'Hern R.P. , Smith I.E. , Ebbs S.R. . Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer. 1993; 67: 801–805.

Fossati R. , Confalonieri C. , Torri V. . Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998; 16: 3439–3460.

Greenberg P.A. , Hortobagyi G.N. , Smith T.L. . Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996; 14: 2197–2205.

Sledge G.W. , Neuberg D. , Ingle J. . Phase III trial of doxorubicin (A) versus paclitaxel (T) versus doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 1a. Abstract 2.

Fornier M. , Seidman A.D. , Esteva F.J. . Weekly (W) Herceptin (H) + 1 hour Taxol (T): phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2–) metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 482a. Abstract.

Perez E.A. , Irwin D.H. , Patel R. . A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 480a. Abstract.

Sikov W. , Akerley W. , Strenger R. . Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC). Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 432a. Abstract.

Löffler T.M. , Freund W. , Dröge C. . Activity of weekly Taxotere (txt) in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 435a. Abstract.

Hryniuk W. , Bush H. . The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2: 1281–1288.

Rahman Z.U. , Frye D.K. , Buzdar A.U. . Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997; 15: 3171–3177.

Bezwoda W.R. . Primary high dose chemotherapy for metastatic breast cancer: update and analysis of prognostic factors. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 445a. Abstract.

Stadtmauer E.A. . Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluor ouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the Philadelphia Intergroup Study (PBT-01). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 1a. Abstract.